About PregLem
PregLem is a company based in Geneve (Switzerland) founded in 2006 was acquired by Gedeon Richter in October 2010. PregLem has raised $57.94 million across 2 funding rounds from investors including MVM Partners, Sofinnova and NeoMed. PregLem operates in a competitive market with competitors including Sprout Pharmaceuticals, Hope Medicine, Rejoni, ObsEva and Gameto, among others.
- Headquarter Geneve, Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$57.94 M (USD)
in 2 rounds
-
Latest Funding Round
$31.89 M (USD), Series B
Dec 04, 2007
-
Investors
MVM Partners
& 4 more
-
Employee Count
Not available
-
Acquired by
Gedeon Richter
(Oct 07, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of PregLem
Unlock access to complete
Funding Insights of PregLem
PregLem has successfully raised a total of $57.94M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $31.89 million completed in December 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PregLem
PregLem has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include MVM Partners, Sofinnova and NeoMed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Private equity investments in healthcare companies are managed.
|
Locked | Locked | Locked | |
|
Stage-agnostic life sciences-focused VC firm investing in North America & Europe
|
Locked | Locked | Locked |
Investor details for PregLem
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PregLem
Investment portfolio details for PregLem
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PregLem
Detailed financials for PregLem
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Preglem Comparisons
Peer comparison for PregLem
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PregLem
PregLem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sprout Pharmaceuticals, Hope Medicine, Rejoni, ObsEva and Gameto, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drugs for hypoactive sexual desire disorder in women are developed.
|
|
| Locked | Locked | Locked |
Monoclonal antibodies are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for women's health conditions are developed using innovative hydrogels.
|
|
| Locked | Locked | Locked |
Therapeutics for women's reproductive health and pregnancy are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for fertility and menopause treatments are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for reproductive health are developed.
|
Detailed competitors of PregLem
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Preglem
Complete news archive for PregLem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PregLem
PregLem was founded in 2006 and raised its 1st funding round 1 year after it was founded.
PregLem is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
PregLem is a funded company, having raised a total of $57.94M across 2 funding rounds to date.
PregLem is dedicated to the development and commercialization of innovative drugs for womens reproductive medicine. It markets ESMYA (ulipristal acetate), an oral selective progesterone receptor modulator (SPRM) for long-term management of uterine fibroids. Its drug pipeline includes PGL2001, an oral, once-a-week steroid sulfatase inhibitor (STS-I) being developed for the management of endometriosis, including the relief of pain associated with the condition (Phase 2a); PGL1001, a somatostatin antagonist (SST-ATG) with the potential to accelerate the recruitment of resting follicles from the ovarian follicular reserve (preclinical).
PregLem's top competitors include Sprout Pharmaceuticals, Rejoni and Hope Medicine.
PregLem has 5 investors. Key investors include MVM Partners, Sofinnova, NeoMed, Sofinnova Partners, and Richter Gedeon.